Chris Morehouse
Overview
Explore the profile of Chris Morehouse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
1337
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hewitt S, Bailey D, Zielinski J, Apte A, Musenge F, Karp R, et al.
Clin Cancer Res
. 2020 Aug;
26(23):6284-6298.
PMID: 32817076
Purpose: While immune checkpoint inhibitors such as anti-PD-L1 are rapidly becoming the standard of care in the treatment of many cancers, only a subset of treated patients have long-term responses....
2.
Naing A, Infante J, Goel S, Burris H, Black C, Marshall S, et al.
J Immunother Cancer
. 2019 Aug;
7(1):225.
PMID: 31439037
Background: The safety, efficacy, pharmacokinetics, and pharmacodynamics of the anti-programmed cell death-1 antibody MEDI0680 were evaluated in a phase I, multicenter, dose-escalation study in advanced solid malignancies. Methods: MEDI0680 was...
3.
Sridhar S, Paz-Ares L, Liu H, Shen K, Morehouse C, Rizvi N, et al.
Clin Lung Cancer
. 2019 Jul;
20(6):e601-e608.
PMID: 31327642
Introduction: Two clinical studies (Study 1108 and ATLANTIC) were analyzed to evaluate the prognostic value of baseline liver metastases (LMs) in advanced/metastatic non-small-cell lung cancer patients treated with durvalumab 10...
4.
Riggs J, Hanna R, Rajan B, Zerrouki K, Karnell J, Sagar D, et al.
Lupus Sci Med
. 2018 Apr;
5(1):e000261.
PMID: 29644082
Objective: We investigated the mechanistic and pharmacological properties of anifrolumab, a fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal antibody in development for SLE. Methods: IFNAR1...
5.
Higgs B, Liu Y, Guo J, Sebastian Y, Morehouse C, Zhu W, et al.
Sci Rep
. 2017 Dec;
7(1):17567.
PMID: 29242501
We aimed to characterize the molecular differences and effects from prednisone treatment among IgG4-related disease with salivary gland lesions (RD-SG), without SG lesions (RD-nonSG), and IgG4-related retroperitoneal fibrosis (RF). RNA...
6.
Wiseman J, Gregersson P, Johansson J, Magnell K, Pilataxi F, Morehouse C, et al.
Transgenic Res
. 2017 Aug;
26(6):791-798.
PMID: 28819706
Humanized mouse models are important tools in many areas of biological drug development including, within oncology research, the development of antagonistic antibodies that have the potential to block tumor growth...
7.
Sands B, Chen J, Feagan B, Penney M, Rees W, Danese S, et al.
Gastroenterology
. 2017 Apr;
153(1):77-86.e6.
PMID: 28390867
Background & Aims: MEDI2070 is a human monoclonal antibody that selectively inhibits interleukin 23 (IL23), a cytokine implicated in the pathogenesis of Crohn's disease (CD). We analyzed its safety and...
8.
Mahmoud T, Wang J, Karnell J, Wang Q, Wang S, Naiman B, et al.
Sci Transl Med
. 2016 Nov;
8(361):361ra137.
PMID: 27798262
Autoantibodies can be present years to decades before the onset of disease manifestations in autoimmunity. This finding suggests that the initial autoimmune trigger involves a peripheral lymphoid component, which ultimately...
9.
Delaney T, Morehouse C, Brohawn P, Groves C, Colonna M, Yao Y, et al.
J Immunol
. 2016 May;
197(1):42-50.
PMID: 27226090
Type I IFNs play a critical role in the immune response to viral infection and may also drive autoimmunity through modulation of monocyte maturation and promotion of autoreactive lymphocyte survival....
10.
Jiang L, Huang J, Higgs B, Hu Z, Xiao Z, Yao X, et al.
PLoS Genet
. 2016 Apr;
12(4):e1005895.
PMID: 27093186
Small cell lung cancer (SCLC) is an aggressive disease with poor survival. A few sequencing studies performed on limited number of samples have revealed potential disease-driving genes in SCLC, however,...